Results 131 to 140 of about 5,425 (143)

European regulatory experience with drugs for central nervous system disorders

Nature Reviews Drug Discovery, 2014
Guido Rasi
exaly  

Effects of long-term exposure to air pollution on natural-cause mortality: an analysis of 22 European cohorts within the multicentre ESCAPE project

Lancet, The, 2014
Ole Raaschou-Nielsen, Massimo Stafoggia, Zorana Jovanovic Andersen   +2 more
exaly  

A European tobacco advertising ban

Ca-A Cancer Journal for Clinicians, 1998
exaly  

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

Lancet, The, 2007
Juan Carlos Tejedor
exaly  

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

Lancet, The, 2014
Jonas Hugosson, Monique J Roobol, Teuvo L J Tammela   +2 more
exaly  

Commentary on “European Consensus Statement on Lung Cancer”

Ca-A Cancer Journal for Clinicians, 1998
exaly  

Primary HPV screening for cervical cancer prevention: results from European trials

Nature Reviews Clinical Oncology, 2009
Elsebeth Lynge, Matejka Rebolj
exaly  

Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis

Lancet, The, 2010
Laura Viviani
exaly  

A bright future for European beamlines

Nature Reviews Materials, 2018
exaly  

European Lead Factory hits its stride

Nature Reviews Drug Discovery, 2016
exaly